BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 27852699)

  • 1. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.
    Balakrishnan A; Goodpaster T; Randolph-Habecker J; Hoffstrom BG; Jalikis FG; Koch LK; Berger C; Kosasih PL; Rajan A; Sommermeyer D; Porter PL; Riddell SR
    Clin Cancer Res; 2017 Jun; 23(12):3061-3071. PubMed ID: 27852699
    [No Abstract]   [Full Text] [Related]  

  • 2. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
    Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
    Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
    Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.
    Shabani M; Naseri J; Shokri F
    Expert Opin Ther Targets; 2015 Jul; 19(7):941-55. PubMed ID: 25835638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
    Dave H; Anver MR; Butcher DO; Brown P; Khan J; Wayne AS; Baskar S; Rader C
    PLoS One; 2012; 7(12):e52655. PubMed ID: 23285131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
    Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
    Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.
    Srivastava S; Salter AI; Liggitt D; Yechan-Gunja S; Sarvothama M; Cooper K; Smythe KS; Dudakov JA; Pierce RH; Rader C; Riddell SR
    Cancer Cell; 2019 Mar; 35(3):489-503.e8. PubMed ID: 30889382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
    Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
    PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
    Berger C; Sommermeyer D; Hudecek M; Berger M; Balakrishnan A; Paszkiewicz PJ; Kosasih PL; Rader C; Riddell SR
    Cancer Immunol Res; 2015 Feb; 3(2):206-16. PubMed ID: 25355068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.
    Choi MY; Widhopf GF; Wu CC; Cui B; Lao F; Sadarangani A; Cavagnaro J; Prussak C; Carson DA; Jamieson C; Kipps TJ
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S167-9. PubMed ID: 26297272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
    Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
    PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.
    Hojjat-Farsangi M; Ghaemimanesh F; Daneshmanesh AH; Bayat AA; Mahmoudian J; Jeddi-Tehrani M; Rabbani H; Mellstedt H
    PLoS One; 2013; 8(4):e61167. PubMed ID: 23593420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
    Zhang S; Chen L; Cui B; Chuang HY; Yu J; Wang-Rodriguez J; Tang L; Chen G; Basak GW; Kipps TJ
    PLoS One; 2012; 7(3):e31127. PubMed ID: 22403610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ROR1 identifies new treatment strategies in hematological cancers.
    Karvonen H; Niininen W; Murumägi A; Ungureanu D
    Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROR1 and ROR2-novel targets for neuroblastoma.
    Dave H; Butcher D; Anver M; Bollard CM
    Pediatr Hematol Oncol; 2019 Sep; 36(6):352-364. PubMed ID: 31441359
    [No Abstract]   [Full Text] [Related]  

  • 17. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
    Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique.
    Aghebati-Maleki L; Younesi V; Jadidi-Niaragh F; Baradaran B; Majidi J; Yousefi M
    Hum Antibodies; 2017; 25(1-2):57-63. PubMed ID: 28128766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model.
    Hassannia H; Amiri MM; Jadidi-Niaragh F; Hosseini-Ghatar R; Khoshnoodi J; Sharifian RA; Golsaz-Shirazi F; Jeddi-Tehrani M; Shokri F
    Immunol Lett; 2018 Jan; 193():35-41. PubMed ID: 29175316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.